KR20220155333A - 항-글리칸 항체 및 이의 용도 - Google Patents

항-글리칸 항체 및 이의 용도 Download PDF

Info

Publication number
KR20220155333A
KR20220155333A KR1020227035436A KR20227035436A KR20220155333A KR 20220155333 A KR20220155333 A KR 20220155333A KR 1020227035436 A KR1020227035436 A KR 1020227035436A KR 20227035436 A KR20227035436 A KR 20227035436A KR 20220155333 A KR20220155333 A KR 20220155333A
Authority
KR
South Korea
Prior art keywords
seq
antibody
antigen
sequence
binding portion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227035436A
Other languages
English (en)
Korean (ko)
Inventor
레오나드 프레스타
토니 리앙
제니퍼 쳉
Original Assignee
피티엠 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피티엠 테라퓨틱스, 인크. filed Critical 피티엠 테라퓨틱스, 인크.
Publication of KR20220155333A publication Critical patent/KR20220155333A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020227035436A 2020-03-17 2021-03-16 항-글리칸 항체 및 이의 용도 Pending KR20220155333A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062990927P 2020-03-17 2020-03-17
US62/990,927 2020-03-17
US202063037374P 2020-06-10 2020-06-10
US63/037,374 2020-06-10
US202063074956P 2020-09-04 2020-09-04
US63/074,956 2020-09-04
PCT/US2021/022627 WO2021188591A1 (en) 2020-03-17 2021-03-16 Anti-glycan antibodies and uses thereof

Publications (1)

Publication Number Publication Date
KR20220155333A true KR20220155333A (ko) 2022-11-22

Family

ID=75581605

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227035436A Pending KR20220155333A (ko) 2020-03-17 2021-03-16 항-글리칸 항체 및 이의 용도

Country Status (8)

Country Link
US (3) US11230608B2 (https=)
EP (1) EP4121460A1 (https=)
JP (2) JP2023518228A (https=)
KR (1) KR20220155333A (https=)
CN (1) CN115698082A (https=)
AU (1) AU2021237566A1 (https=)
CA (1) CA3170434A1 (https=)
WO (1) WO2021188591A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023133452A1 (en) * 2022-01-06 2023-07-13 PTM Therapeutics, Inc. Methods of treating solid tumors and compositions thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO2013078425A1 (en) * 2011-11-22 2013-05-30 University Of Maryland, Baltimore Lambodies with high affinity and selectivity for glycans and uses therefor

Also Published As

Publication number Publication date
US20220340683A1 (en) 2022-10-27
US20210292432A1 (en) 2021-09-23
JP2023518228A (ja) 2023-04-28
WO2021188591A1 (en) 2021-09-23
AU2021237566A1 (en) 2022-09-29
CN115698082A (zh) 2023-02-03
CA3170434A1 (en) 2021-09-23
EP4121460A1 (en) 2023-01-25
US11230608B2 (en) 2022-01-25
US20250034276A1 (en) 2025-01-30
JP2026031937A (ja) 2026-02-25

Similar Documents

Publication Publication Date Title
JP6230488B2 (ja) アンタゴニスト抗ｉｌ−７受容体抗体および方法
KR102663440B1 (ko) 인간화된 항-ccr7 리셉터 항체
US20240117030A1 (en) Multispecific antibodies and uses thereof
JP2021514664A (ja) 抗クローディン１８．２抗体及びその使用
US12043666B2 (en) Anti-IL1RAP antibody
TW201902915A (zh) 針對淋巴細胞活化基因-3（lag-3）之抗體藥劑及其用途
WO2019024911A1 (zh) B7h3抗体-药物偶联物及其医药用途
JP2022101631A (ja) 抗ｐｄ‐ｌ１抗体とｉｌ‐７との融合
CN115803057A (zh) 治疗多发性骨髓瘤的方法
JP2021500916A (ja) 抗ｔｉｍ−３抗体及びその使用
KR20220114559A (ko) Cd38에 결합하는 중쇄 항체
KR20230007531A (ko) 아밀로이드 침착 질환의 치료를 위한 방법 및 조성물
MX2010011309A (es) Inhibidores de gm-csf e il-17 para terapia.
JP2021513324A (ja) 自己免疫疾患およびがんを治療するための抗ｃｘｃｌ１３抗体
JP2026031937A (ja) 抗グリカン抗体及びそれらの使用
WO2025042888A1 (en) Methods of treating digestive diseases and compositions thereof
BR122024014186A2 (pt) Proteínas de ligação ao receptor de il27 e seu uso, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição farmacêutica e seu uso
TW202444410A (zh) 一種治療系統性紅斑狼瘡的方法
JP2025505928A (ja) 抗ｃｄ４０×ｃｌｄｎ１８．２二重特異性抗体及びその使用
BR112023001737B1 (pt) Proteínas de ligação ao receptor de il27
KR20250034263A (ko) 다중특이적 항체 및 그의 용도
HK40119918A (zh) 多特异性抗体及其用途
HK40119132A (zh) 与il-4、il-13和/或tslp结合的多特异性抗体及其用途
CN120390650A (zh) 治疗非霍奇金淋巴瘤的方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902